Want to see AU:OSL full AI Analyst Report?
Top Page
OncoSil Medical Ltd
(Sydney:OSL)
Select Model
Select Model
Rating:47Neutral
Price Target:
AU$1.00
â–¼(-13.79% Downside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by weak financial performance—ongoing losses, negative gross profit, and persistent negative operating/free cash flow—despite a low-debt balance sheet. Technicals provide modest support with the price above key longer-term moving averages, but near-term momentum is not strong. Valuation metrics are unfavorable because the company is loss-making (negative P/E) and there is no dividend yield provided.
Positive Factors
Accelerating revenue growth
Revenue is expanding at a meaningful rate, indicating increasing commercial activity and potential product adoption. Although the base remains small, sustained growth could improve operating leverage over time if OncoSil converts its focused oncology offering into broader recurring demand.
Negative Factors
Persistent unprofitability
Negative gross profit and large operating losses show that current revenue is not yet sufficient to cover the economics of the business. Continued losses may limit internal reinvestment and make future improvement dependent on materially higher sales, better margins, or lower operating costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating revenue growth
Revenue is expanding at a meaningful rate, indicating increasing commercial activity and potential product adoption. Although the base remains small, sustained growth could improve operating leverage over time if OncoSil converts its focused oncology offering into broader recurring demand.
Read all positive factors
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$32.28M
Dividend YieldN/A
Average Volume (3M)175.32K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue Growth43.92%
EPS Growth65.23%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.48
Shares Outstanding30,890,978
10 Day Avg. Volume66,258
30 Day Avg. Volume175,323
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)3.22
Price to Sales (P/S)9.54
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)AU$4.40M
OncoSil Medical Ltd Business Overview & Revenue Model
Company Description
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for ...
OncoSil Medical Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.68M | 1.17M | 516.63K | 367.68K | 231.79K |
| Gross Profit | -6.20M | -1.08M | -993.00K | -1.22M | -6.73M |
| EBITDA | -14.36M | -15.06M | -12.91M | -11.17M | -11.41M |
| Net Income | -10.86M | -15.10M | -11.91M | -11.34M | -10.73M |
Balance Sheet | |||||
| Total Assets | 10.31M | 7.15M | 6.72M | 11.47M | 13.07M |
| Cash, Cash Equivalents and Short-Term Investments | 6.48M | 5.11M | 4.50M | 9.39M | 11.28M |
| Total Debt | 14.78K | 69.92K | 70.67K | 170.81K | 304.21K |
| Total Liabilities | 5.31M | 4.04M | 1.98M | 1.59M | 1.91M |
| Stockholders Equity | 5.00M | 3.10M | 4.74M | 9.88M | 11.16M |
Cash Flow | |||||
| Free Cash Flow | -10.47M | -12.08M | -11.02M | -11.37M | -10.12M |
| Operating Cash Flow | -10.47M | -12.06M | -10.82M | -11.32M | -10.11M |
| Investing Cash Flow | -1.46K | -14.96K | -197.06K | -57.82K | -5.83K |
| Financing Cash Flow | 11.86M | 12.73M | 6.13M | 9.49M | 9.16M |
OncoSil Medical Ltd Technical Analysis
Negative
1.16
Price Trends
0.73
Negative
0.96
Negative
Market Momentum
-0.05
Positive
20.34
Positive
5.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:OSL, the sentiment is Negative. The current price of 1.16 is above the 20-day moving average (MA) of 0.63, above the 50-day MA of 0.73, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 20.34 is Positive, neither overbought nor oversold. The STOCH value of 5.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:OSL.
OncoSil Medical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$711.57M | 97.17 | 8.45% | ― | 12.94% | -44.50% | |
63 Neutral | AU$191.98M | 30.49 | 7.55% | ― | 19.23% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$174.76M | -20.59 | -46.84% | ― | ― | 20.40% | |
47 Neutral | AU$32.28M | -2.18 | -245.90% | ― | 43.92% | 65.23% | |
45 Neutral | AU$20.14M | -0.43 | -259.31% | ― | 14.85% | -1.74% | |
42 Neutral | AU$65.38M | -3.25 | -62.14% | 0.64% | 12.05% | -31.71% |
* Healthcare Sector Average
AU:OSL
OncoSil Medical Ltd
1.05
-0.19
-15.18%
AU:PNV
Polynovo
1.03
-0.44
-29.93%
AU:IPD
Impedimed Limited
0.01
-0.03
-65.00%
AU:CYC
Cyclopharm Limited
0.52
-0.36
-40.91%
AU:ARX
Aroa Biosurgery Ltd
0.56
-0.14
-20.71%
AU:EMV
EMvision Medical Devices Ltd.
1.88
-0.10
-5.05%
OncoSil Medical Ltd Corporate Events
OncoSil Medical Plans ASX Share Placement to Raise Capital
Sep 7, 2026
OncoSil Medical Ltd has announced a proposed placement of up to 4,000,000 ordinary fully paid shares on the ASX. The new securities are scheduled for issue on 10 September 2026, subject to ASX processes and quotation.The capital raising via this s...
OncoSil Medical Raises $5.6m to Drive Cancer Device Commercialisation
Sep 7, 2026
OncoSil Medical has secured $5.6 million in new capital from its three largest institutional investors through a $4.0 million share placement at a premium to its last traded price and the early exercise of $1.6 million in listed options. The fundi...
OncoSil Seeks CMS Pass-Through Status to Support U.S. Launch of Cancer Device
Sep 2, 2026
OncoSil Medical has submitted an application to the U.S. Centers for Medicare Medicaid Services for Transitional Pass-Through Payment status for its OncoSil™ device, following recent FDA Humanitarian Device Exemption approval for treating u...
OncoSil Seeks US Medicare Pass-Through Status for Targeted Cancer Device
Sep 2, 2026
OncoSil Medical has moved to strengthen its U.S. commercial strategy by submitting an application to the Centers for Medicare Medicaid Services for Transitional Pass-Through payment status for its OncoSil™ device. The filing follows recent ...
OncoSil lodges updated ASX corporate governance statement for FY 2026
Aug 28, 2026
OncoSil Medical has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming that the document is available on its website and current as of 28 August 2026. The filing, together with the completed Appendix 4G, ...
OncoSil narrows annual loss as revenue and other income surge
Aug 28, 2026
OncoSil Medical Ltd reported a 43.9% increase in revenue from ordinary activities to $1.68 million for the year ended 30 June 2026, alongside a sharp 678.2% rise in other income and interest revenue to $3.54 million, reflecting stronger income str...
OncoSil Seeks ASX Quotation for Small Issue of New Shares
Aug 17, 2026
OncoSil Medical Ltd has applied for quotation of 500 new ordinary fully paid shares on the Australian Securities Exchange, with the securities issued on 17 August 2026. The small issuance, arising from the exercise or conversion of existing instru...
OncoSil Flags FDA Milestone While Stressing Investor Caution
Aug 17, 2026
OncoSil Medical has prepared an investor webinar titled “FDA Approval: A New Chapter for OncoSil,” highlighting the U.S. regulator’s clearance as a key milestone for the company. The presentation emphasises that it is information...
OncoSil Wins Landmark U.S. FDA Approval for Rare Bile Duct Cancer Device
Aug 16, 2026
OncoSil Medical has secured U.S. FDA Humanitarian Device Exemption approval for its OncoSil device to treat unresectable, non-metastatic distal cholangiocarcinoma, a rare bile duct cancer with limited options and a median overall survival of 6.7 m...
OncoSil Medical Posts Strong FY26 Growth as Pancreatic Cancer Device Gains Regulatory and Clinical Traction
Jul 29, 2026
OncoSil Medical reported strong commercial momentum in the June quarter, with FY26 unit sales rising 53% and revenue up 44%, driven by growing adoption of its OncoSil device across European treatment centres and supported by expanding clinical evi...
OncoSil Study Backs Higher-Concentration Formulations to Boost Efficiency
Jul 23, 2026
OncoSil Medical has reported results from an independent study by Institut Galien Paris-Saclay showing that OncoSil device suspensions can be formulated at significantly higher microparticle concentrations without increasing viscosity at injection...
OncoSil Medical Lists Additional Ordinary Shares on ASX
Jul 23, 2026
OncoSil Medical Ltd has applied for quotation on the ASX of 1,048 new fully paid ordinary shares under the ticker OSL, with an issue date of 23 July 2026. The small-sized share issuance, arising from the exercise or conversion of existing options ...
OncoSil Highlights Financial Position and Niche Cancer Device Focus
Jul 14, 2026
OncoSil Medical Ltd, a Class III medical device company, is focused on localised treatments for unresectable locally advanced pancreatic cancer and distal cholangiocarcinoma via its flagship OncoSil device, approved in over 34 countries and recogn...
OncoSil to Showcase Real-World Pancreatic Cancer Data at Major Nuclear Medicine Congress
Jul 13, 2026
OncoSil Medical will present initial outcomes from its ongoing OSPREY registry at the 2026 European Association of Nuclear Medicine Congress in Vienna, highlighting real-world use of its OncoSil device in combination with gemcitabine-based chemoth...
OncoSil validates scalable Australian manufacturing for pancreatic cancer device
Jul 12, 2026
OncoSil Medical has completed three manufacturing validation cycles with partner Cyclotek, producing more than 50 validation doses of its OncoSil device and establishing a dedicated Australian manufacturing capability. The company invested about $...
OncoSil trial data at ESMO GI 2026 bolster case for FOLFIRINOX label expansion
Jul 5, 2026
OncoSil Medical reported updated results from its Phase II TRIPP-FFX trial, presented at the ESMO GI 2026 congress, evaluating the addition of the OncoSil device to standard FOLFIRINOX chemotherapy in unresectable locally advanced pancreatic cance...
OncoSil Seeks First U.S. Approval With FDA Filing for Cancer Device
Jul 2, 2026
OncoSil Medical has completed its Humanitarian Device Exemption application submission to the U.S. Food and Drug Administration for its OncoSil device in the treatment of distal cholangiocarcinoma. The filing moves the device into the FDA review p...
OncoSil Joins EU PALACROS Consortium With Cost-Efficient Pancreatic Cancer Trial
Jul 1, 2026
OncoSil Medical has been selected to join PALACROS, a major EU-funded academic consortium aimed at improving outcomes for patients with locally advanced pancreatic cancer across Europe. The company will participate via the PULSE Phase II trial, a ...
OncoSil trial data wins ESMO GI spotlight with promising pancreatic cancer results
Jun 29, 2026
OncoSil Medical said initial results from its TRIPP-FFX trial have been published as an abstract on the European Society for Medical Oncology Gastrointestinal Cancers Congress website. The open-label, multi-centre study evaluates adding targeted i...
OncoSil to Release 41,067 Escrowed Shares Issued as Director Fees
Jun 29, 2026
OncoSil Medical Limited, a specialist in targeted intratumoural radiotherapy for pancreatic cancer, focuses on its CE-marked OncoSil device, which allows higher radiation doses directly into tumours while sparing nearby organs. The company operate...
OncoSil flags FDA progress and early TRIPP-FFX data in investor update
Jun 9, 2026
OncoSil Medical Limited has released an investor presentation and will host a webinar to update investors on recent interactions with the U.S. Food and Drug Administration and to discuss initial results from its TRIPP-FFX clinical trial. The updat...
OncoSil Nears Final FDA HDE Decision for Rare Bile Duct Cancer Device
Jun 9, 2026
OncoSil Medical has reached the final stage of U.S. FDA review for its Humanitarian Device Exemption application for the OncoSil device in distal cholangiocarcinoma, a rare cancer with poor prognosis and limited treatment options. The FDA has conf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.